Modular Facilities: Flexible Drug Manufacturing Platforms of the Future

Roots Analysis has announced the addition of “Modular Facilities in Pharmaceutical / Biotechnology Industry, 2017-2030”report to their list of offerings. The report features an extensive study on current landscape and the future outlook of the rapidly growing market of modular facility / cleanroom manufacturers in the pharmaceutical / biotechnology industry.

Pemba Lahmo, the principal analyst stated that, “Modular facilities have demonstrated tremendous potential in several fields; specifically, the shorter time taken to establish such facilities has a significant impact on expediting various operational processes. Over the years, the interest in such facilities has also gradually risen amongst drug manufacturers within the pharmaceutical / biopharmaceutical industry. In fact, various companies have already transitioned from establishing conventional manufacturing facilities (focused on the large-scale production of a single product) to using small, flexible and modular facilities that can handle multiple products, simultaneously.”

The report presents an elaborate compilation of research, analysis and opinions on several key aspects of the market. Among other things, the report includes the following:

• A review of the competitive market landscape of modular facility / modular cleanroom manufacturers with information on their geographical location, establishment year, size and type of industries served. It also includes information on regulatory certifications and recent projects undertaken by these companies.
• Elaborate profiles of established players that offer a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries; each profile includes a brief overview of the company, information on its financial status, comprehensive modular services portfolio, recent collaborations, information on capability / facility expansions and an informed future outlook.
• An analysis of the most active regions based on the locations of modular manufacturing solution providers; the report contains schematic representations of world maps that clearly indicate the modular facility / cleanroom manufacturing hubs.
• A review of emerging trends, including the combination of single-use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose and multi-product modular facilities.
• A discussion on key points that should be considered to facilitate the shift from using conventional facilities to modular facilities. It also includes a case study on JHL Biotech’s KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China.
• A detailed discussion on the various growth drivers, such as the development of a wide range of patient specific andorphan drugs, and the increasing focus on optimizing drug development costs and reducing the time to market.
• A detailed analysis of the collaborations and agreements, covering facility construction agreements, service alliances and acquisitions, which have been established amongst various stakeholders in the past few years.

Lahmo further added, “Companies manufacturing niche and emerging therapeutic classes, such as personalized therapies, along with the rising number of biosimilars, hold significant promise for modular facility manufacturers. The adoption of such facilities is also likely to increase in emerging regions, some of which have struggled to meet GMP standards. In addition, CMOs, adopting modular facilities to reduce initial capital investment and handle multiple products, are expected to create incremental business opportunities for modular facility manufacturers.”

The report highlights the contributions of several players in the field; some of the examples are listed below:

• GE Healthcare Life Sciences
• G-CON Manufacturing
• Pharmadule Morimatsu
• ModWave / KeyPlants
• Jacobs Engineering Group
• NNE
• IPM Technologies
• Germfree Laboratories
• Biologics Modular
• WH Partnerships

The opinions and insights discussed in this report were influenced by discussions conducted with industry experts.

The report features detailed transcripts of interviews held with Maik Jornitz (CEO, G-CON Manufacturing), Pär Almhem (President, ModWave), Sulogna Roy (Business Development Engineer, Zeton) and Vernon Solomon (President, Environmental Systems Corporation).

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/modular-facilities-in-pharmaceutical--biotechnology-industry-2017-2030/178.html or email sales@rootsanalysis.com

Contact:

Gaurav Chaudhary

+1-604-595-4954

Gaurav.Chaudhary@rootsanalysis.com